Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • CG-806 for B-cell Tumors
    • CG-806 for Myeloid Tumors
    • APTO-253
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • CG-806 for CLL & NHL
    • CG-806 for AML
    • APTO-253 for AML & MDS
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Apr 08, 2021 7:30am EDT

Aptose Reports Results for the Fourth Quarter and Full Year 2020

Mar 23, 2021 4:01pm EDT

Aptose Expands Senior Leadership Team

Mar 16, 2021 7:30am EDT

Aptose to Release Fourth Quarter and Year End December 31, 2020 Financial Results and Hold Conference Call on March 23, 2021

Mar 02, 2021 4:02pm EST

Aptose Presents Highlights from ASH and Corporate Update Event

Dec 06, 2020 5:30pm EST

Aptose to Hold Corporate Update Sunday, December 6th

Dec 01, 2020 7:30am EST

Aptose Reports Results for the Third Quarter 2020

Nov 10, 2020 4:01pm EST

Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting

Nov 04, 2020 10:17am EST

Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020

Oct 27, 2020 4:01pm EDT

Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia

Oct 19, 2020 7:00am EDT
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...20
Next
© 2021 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap